Quiz derived from the IPV Injectable Polio Vaccine Presentation given in August 2013 from Small Group Meeting at Chandigarh

1. Polio – End Game Quiz
Dr Gaurav Gupta
Source: IAP ADVAC Program

2. All of the following are risks for polio re-emergence
after termination of wild virus transmission:
a. Laboratories that work with wild polioviruses
b. Chronic immune deficient shedders
c. Continued use of oral polio vaccines
d. Continued use of wild polio viruses to make
inactivated polio vaccine
e. Bioterrorism
f. All of the above

3. All of the following are risks for polio re-emergence
after termination of wild virus transmission:
a. Laboratories that work with wild polioviruses
b. Chronic immune deficient shedders
c. Continued use of oral polio vaccines
d. Continued use of wild polio viruses to make
inactivated polio vaccine
e. Bioterrorism
f. All of the above

4. Circulating vaccine-derived polioviruses have the
same characteristics as wild polioviruses
False
True

5. Circulating vaccine-derived polioviruses have the
same characteristics as wild polioviruses
False
True

6. The most common cause of circulating vaccine
derived poliovirus outbreaks in recent years is:
• Type 1
• Type 2
• Type 3
• Mixed types

7. The most common cause of circulating vaccine
derived poliovirus outbreaks in recent years is:
• Type 1
• Type 2
• Type 3
• Mixed types

8. Oral polio vaccines are characterized by all of the
following EXCEPT:
• Have lower efficacy in tropical countries than in
industrialized countries
• Spread from vaccinees to non-vaccinees, thereby
enhancing immunity
• Cause vaccine-associated paralytic polio (VAPP) in
vaccine recipients but not contacts
• Can lead to viruses with the transmissibility and
neurovirulence characteristics of wild viruses

9. • Oral polio vaccines are characterized by all of the
following EXCEPT:
• Have lower efficacy in tropical countries than in
industrialized countries
• Spread from vaccinees to non-vaccinees, thereby
enhancing immunity
• Cause vaccine-associated paralytic polio (VAPP) in
vaccine recipients but not contacts
• Can lead to viruses with the transmissibility and
neurovirulence characteristics of wild viruses

10. Cases of vaccine-associated paralytic polio are as
clinically severe as cases of wild virus polio
False
True

11. Cases of vaccine-associated paralytic polio are as
clinically severe as cases of wild virus polio
False
True

12. All of the following are true about inactivated
polio vaccine (IPV) except:
• IPV is made from wild polio viruses
• IPV must be given by injection
• IPV is equivalent to oral polio vaccine (OPV) in
inducing immunity in the oral cavity
• IPV is equivalent to OPV in inducing immunity
in the intestine

13. All of the following are true about inactivated
polio vaccine (IPV) except:
• IPV is made from wild polio viruses
• IPV must be given by injection
• IPV is equivalent to oral polio vaccine (OPV) in
inducing immunity in the oral cavity
• IPV is equivalent to OPV in inducing immunity
in the intestine

14. All of the following are true with regard to VAPP
EXCEPT:
• It can occur in contacts as well as recipients
• Persons with B cell immune deficiencies have
the highest risk
• The most common type associated with VAPP
is type 1
• Most cases of VAPP have no identified risk
factors

15. All of the following are true with regard to VAPP
EXCEPT:
• It can occur in contacts as well as recipients
• Persons with B cell immune deficiencies have
the highest risk
• The most common type associated with VAPP
is type 1
• Most cases of VAPP have no identified risk
factors

16. Immune deficient persons can excrete
polioviruses for many years and can develop
clinical polio years after their initial infection.
False
True

17. Immune deficient persons can excrete
polioviruses for many years and can develop
clinical polio years after their initial infection.
False
True

18. All of the following are being considered for the
polio endgame EXCEPT:
• Development of antiviral drugs to treat immune
deficient chronic poliovirus shedders
• Stopping OPV as soon as it is safe to do so
• Establishing special procedures to contain virus in
laboratories
• Making IPV affordable for developing countries
• Establishing a stockpile of trivalent Oral Polio
Vaccine

19. All of the following are being considered for the
polio endgame EXCEPT:
• Development of antiviral drugs to treat immune
deficient chronic poliovirus shedders
• Stopping OPV as soon as it is safe to do so
• Establishing special procedures to contain virus in
laboratories
• Making IPV affordable for developing countries
• Establishing a stockpile of trivalent Oral Polio
Vaccine

20. All of the following are ways to make IPV more
affordable EXCEPT:
• Oral delivery
• Intradermal delivery
• Decrease number of doses
• Use seed strains other than the wild virus
• Add adjuvants to the vaccine

21. All of the following are ways to make IPV more
affordable EXCEPT:
• Oral delivery
• Intradermal delivery
• Decrease number of doses
• Use seed strains other than the wild virus
• Add adjuvants to the vaccine